Safety and immunogenicity of NVX-CoV2373 (TAK-019) vaccine in healthy Japanese adults: Interim report of a phase I/II randomized controlled trial.

导出 OA

翻译打印收藏纠错

作者： Taisei,Masuda ^[1] ; Kyoko,Murakami ^[2] ; Kenkichi,Sugiura ^[3] ; Sho,Sakui ^[4] ; Ron P,Schuring ^[5] ; Mitsuhiro,Mori ^[6]

作者单位： Japan Development, Global Vaccine Business Unit, Takeda Pharmaceutical Company Ltd, Japan. Electronic address: taisei.masuda@takeda.com. ^[1] Japan Medical and Policy Affairs, Medical Affairs Office, Global Vaccine Business Unit, Takeda Pharmaceutical Company Ltd, Japan. Electronic address: kyoko.murakami@takeda.com. ^[2] Statistical and Quantitative Sciences, Data Sciences Institute, Takeda Pharmaceutical Company Ltd, Japan. Electronic address: kenkichi.sugiura@takeda.com. ^[3] Statistical and Quantitative Sciences, Data Sciences Institute, Takeda Pharmaceutical Company Ltd, Japan. Electronic address: sho.sakui@takeda.com. ^[4] Clinical Development, Global Vaccine Business Unit, Takeda Pharmaceuticals International AG, Switzerland. Electronic address: ron.schuring@takeda.com. ^[5] Japan Development, Global Vaccine Business Unit, Takeda Pharmaceutical Company Ltd, Japan. Electronic address: mitsuhiro.mori@takeda.com. ^[6]

关键词 COVID-19 Immunogenicity Japanese adults NVX-CoV2373 SARS-CoV-2 Safety

主题词成年人(Adult);抗体, 病毒(Antibodies, Viral);双盲法(Double-Blind Method);人类(Humans);日本(Japan)

DOI 10.1016/j.vaccine.2022.04.035

PMID 35501178

发布时间 2022-12-21

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交